NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
NORTHWEST BIOTHERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.16−0.00 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $254.79M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0739 (−32.27%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
NORTHWEST BIOTHERAPEUTICS INC grew revenue 98.6% to $2.17M over the twelve months to Jun 30, 2026. Free cash flow was -$49.77M.
Revenue
$2.17M
+98.6% vs. a year earlier
Operating income
-$50.33M
TTM Q2 2026
Free cash flow
-$49.77M
TTM Q2 2026
EPS, diluted
-$0.04
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $254.79M
- P/E ratio
- –
- Price to sales
- 117.25
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -19.53%
Fundamentals
- Revenue
- $2.17M
- Net income
- -$37.73M
- EPS, diluted
- -$0.04
- Free cash flow
- -$49.77M
- Book value per share
- -$0.03
- Diluted shares
- 1.64B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$2.17M+98.6% YoY
Gross profit
–
Operating income
-$50.33M
Net income
-$37.73M
EPS, diluted
–
Free cash flow
-$49.77M
Reported periodTrailing twelve months